These studies suggest that PKCα activity in bladder cancer may be a biomarker for poor prognosis and anticancer drug resistance and that PKCα inhibition may be a useful therapeutic option for bladder cancer. This evidence concerns the gene PRKCA and urinary bladder carcinoma.